⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Rigel Appoints Michael P. Miller to the Board of Directors
prnewswire.com
RIGL
Zapata Secures Foundational Patent for Interoperable Quantum Software Across Key Global Markets
globenewswire.com
MSFT
NVDA
RIGL
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
prnewswire.com
MRK
LLY
RIGL
AZN
GILD
ABBV
PFE
TMO
BMY
NVS
BIIB
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
globenewswire.com
JNJ
BIIB
NVS
VTRS
RPRX
ABBV
AZN
MRK
RIGL
GSK
REGN
GILD
AMGN
LLY
BMY
XBI
IBB
Rigel Provides Business Update and 2026 Outlook
prnewswire.com
RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com
RIGL
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
globenewswire.com
RIGL
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
businesswire.com
RIGL
GILD
ARCX
SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Ongoing Global Trials and Promising Candidates Like Sovleplenib Create Strong Investment and Innovation Opportunities
globenewswire.com
RIGL
GILD
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
prnewswire.com
RIGL